SEC
NBIX icon

Seven Eight Capital’s Neurocrine Biosciences NBIX Stock Holding History

Seven Eight Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-64,883
Closed -$7.48M – 408
2024
Q3 		$7.48M Buy
64,883
+57,021
+725% +$7.82M 0.67% 7
2024
Q2 		$1.08M Buy
7,862
+6,190
+370% +$849K 0.11% 333
2024
Q1 		$231K Sell
1,672
-5,543
-77% -$757K 0.02% 562
2023
Q4 		$951K Buy
+7,215
New +$830K 0.11% 271
2023
Q3 		– Sell
-6,430
Closed -$606K – 689
2023
Q2 		$606K Buy
+6,430
New +$628K 0.1% 273
2023
Q1 		– Sell
-1,804
Closed -$215K – 550
2022
Q4 		$215K Buy
+1,804
New +$211K 0.06% 363
2021
Q4 		– Sell
-3,616
Closed -$347K – 603
2021
Q3 		$347K Buy
+3,616
New +$342K 0.03% 483
2020
Q4 		– Sell
-20,300
Closed -$1.95M – 554
2020
Q3 		$1.95M Buy
+20,300
New +$2.35M 0.42% 36
2020
Q1 		– Sell
-66,038
Closed -$7.1M – 618
2019
Q4 		$7.1M Buy
66,038
+8,969
+16% +$939K 0.38% 66
2019
Q3 		$5.14M Buy
+57,069
New +$5.33M 0.27% 106
2018
Q4 		– Sell
-29,000
Closed -$3.57M – 656
2018
Q3 		$3.57M Buy
+29,000
New +$3.29M 0.22% 141
2018
Q1 		– Sell
-31,500
Closed -$2.44M – 481
2017
Q4 		$2.44M Buy
+31,500
New +$2.15M 0.25% 143
2017
Q2 		– Sell
-300
Closed -$13K – 642
2017
Q1 		$13K Buy
+300
New +$12.9K ﹤0.01% 475
2015
Q4 		– Sell
-1,000
Closed -$40K – 637
2015
Q3 		$40K Buy
+1,000
New +$48.3K 0.03% 362
2015
Q2 		– Sell
-6,700
Closed -$266K – 620
2015
Q1 		$266K Buy
+6,700
New +$240K 0.44% 73

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Seven Eight Capital's NBIX Position: Q4 2024 in Review

Seven Eight Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 64,883 shares — an estimated $7.48M sold.

Seven Eight Capital first reported a position in NBIX in Q1 2015 and held it in 15 quarters. The position peaked at $7.48M in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Seven Eight Capital reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 64,883 Neurocrine Biosciences shares in Q4 2024, an estimated $7.48M.
  • Seven Eight Capital first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 15 quarters.
  • Seven Eight Capital's Neurocrine Biosciences position peaked at $7.48M in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.